Covid Vaccine Will be The “October Surprise” One Way or the Other

With the announcement of positive results from a small clinical trial for its experimental Covid vaccine this week, Moderna set the stage for what to expect in the next 2-3 months. Moderna may be in the news more than others, but others are not behind. Oxford-Astra Zeneca announced the start of a 10,000 patient multi-national … Read more

What is the Actual Cost of Clinical Trials?

The most expensive component of the development program for any new medical product is the clinical trials, particularly the pivotal clinical trials, that could recruit hundreds if not thousands of patients per trial and take 1-2 years to complete. Most industry estimates claim that the pivotal clinical trials account for more than 70% of the … Read more

Too Many COVID Clinical Trials Creating “Traffic Jams”?

Well, not literally, but the various clinical trials being scheduled this summer to evaluate the various vaccine and therapeutic agents for COVID-19 have created a stiff competition for volunteers among the various contenders. Of the more than 130 vaccines for COVID-19 in development, about 17 vaccines are currently in human trials, of which about 6 … Read more

Stem cell clinics should file an IND, Now

Stem cell clinics should file INDs immediately, patients looking for stem cell treatments should only do so for those offered under INDs, patients should ask for informed consent, not pay for the treatment, and report adverse events. Or so FDA would want to see. In an article last week in the Journal of American Medical … Read more

Gottlieb and McClellan Critique FDA’s Requirements for COVID Clinical Trials

In a rare criticism of FDA’s requirements for clinical trials, two former commissioners of FDA, Scott Gottlieb and Mark McClellan, argue that FDA should allow practical trial designs of the kind used to evaluate dexamethasone treatment in COVID patients in the UK where data collection was “limited to most important measures of disease severity and … Read more

FDA Agrees, Video Games are Good for Children

In a first of its kind, this week FDA approved a video game as a medical device for the treatment of children with ADHD. Besides the happy children who have one more reason to play more video games (as if they needed one), this presents a new opportunity for game developers. With this decision, FDA … Read more

Fake US Agent Used for FDA Registration by Chinese Companies

More than 1300 Chinese companies used one fictitious address and US Agent information to register with the FDA and exported products to the US that did not meet US requirements, and it may be the tip of an iceberg. Preliminary searches on FDA’s database for registered device manufacturers include 13,751 Chinese device companies, which represent … Read more

Publication Bias Versus Deficient Peer Review: Chloroquine Data Lessons

A much-publicized data on the risk of chloroquine therapy in COVID had to be retracted due to questions about the underlying data creating much more than an embarrassment for the authors and the publishers. It once again highlighted how in the race to publish first; journals cut corners in the peer-review. There were several obvious … Read more

Innovio’s Fate Rests on a Contractor: Client-Contractor Relationship 101 

This week Innovio Pharmaceuticals and its manufacturing vendor, VGXI, got into a public disagreement regarding the terms of their contract which is a primer on vendor management for any company working with vendors in mission critical roles. Innovio would like to move commercial production of the most promising product in its portfolio to new vendors … Read more

Use of Surrogate Endpoints for FDA Approval is Common in Cancer Drugs

About 2 out of 3 cancer drug approvals between 1992 and 2019 were based on surrogate endpoints and about 1 out of 3 surrogate endpoints were used first-time for market approval. A recent survey challenges the wide use of surrogate endpoints over direct measures such as overall survival. The authors found that about half of … Read more